Suven Life Sciences on Wednesday said it has received one product patent from Europe, and two patents from Eurasia, related to new entities for the treatment of neuro-degenerative diseases. The patents are from the class of selective 5-HT4 compounds, Alpha4Beta2 and H3 Inverse agonist compounds, and are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with neuro-degenerative disorders, such as Alzheimer’s, attention deficient hyperactivity disorder, Huntington’s disease, major depressive disorder, Parkinson’s and schizophrenia. With the new patents, the company has a total of 21 granted patents from Europe and 19 from Eurasia. Shares of Suven Life Sciences closed at ₹207, up 1.4 per cent on the NSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.